Issue: 2006 > July-August > review

Guidelines for treatment with infliximab for Crohns disease



REVIEW
D.W. Hommes, B. Oldenburg, A.A. van Bodegraven, R.A. van Hogezand, D.J. de Jong, M.J.L. Romberg-Camps, J. van der Woude, G. Dijkstra
AbstractPDF

Abstract

Infliximab is an accepted induction and maintenance treatment for patients with Crohns disease. The effectiveness of infliximab has been demonstrated for both active luminal disease and for enterocutaneous fistulisation. In addition, infliximab can be administered for extraintestinal symptoms of Crohns disease, such as pyoderma gangrenosum, uveitis and arthropathy. Maintenance treatment with infliximab is effective and is
regarded as safe as long as the necessary safety measures are heeded. Infusion reactions occur in 3 to 17% of the patients and are associated with the formation of antibodies to infliximab. A reduction in infusion reactions is possible by the concurrent administration of steroids and the use of immunosuppressants (azathioprine, 6-mercaptopurine,
methotrexate). Furthermore, immunosuppressants increase the duration of the response to infliximab. For these reasons, the concomitant use of immunosuppressants with infliximab is recommended. Infections and most specifically tuberculosis need to be ruled out before infliximab is administered. Up to now, there are no indications for a connection between an increased risk for malignancies and treatment with infliximab.